mRNA firm GreenLight Biosciences to go public in $1.2B SPAC deal

Just over a year after expanding its messenger RNA, or mRNA, platform from exclusively agricultural applications to include biotech ones, GreenLight Biosciences is going public in a reverse merger with a special-purpose acquisition company, or SPAC.